Skip to content

Study on the dynamic equilibrium mechanism of the "hypothalamus-brainstem" sub-network of acupuncture for perimenopausal insomnia

Study on the dynamic equilibrium mechanism of the "hypothalamus-brainstem" sub-network of acupuncture for perimenopausal insomnia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073675
Enrollment
Unknown
Registered
2023-07-18
Start date
2023-07-20
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perimenopausal insomnia

Interventions

Real acupuncture treatment group:Acupuncture
sham acupuncture treatment group:Sham Acupuncture

Sponsors

Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Female, 40 years = age = 60 years,right-handed; (2) Meets diagnostic criteria for STRAW+10 and ICSD-3; (3) Pittsburgh Sleep Quality Index (PSQI) score >7; (4) Not taking any medication for at least 2 weeks days prior to entering the study; (5) Voluntarily participated in this study and signed an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with bilateral oophorectomy, organic ovarian lesions, premature ovarian failure, polycystic ovary syndrome, and hypothalamic amenorrhoea; (2) Those with hypertension, diabetes mellitus, coronary heart disease, obesity (BMI = 28), and other systemic diseases; (3) Those with combined cardiovascular, cerebrovascular, hepatic, renal, and hematopoietic systems and other life-threatening severe primary diseases; (4) Those who are unconscious and unable to express subjective symptoms of discomfort; (5) The person himself/herself and his/her first-degree immediate family members have a history of psychiatric system diseases, organic neuropathy, etc; (6) Insomnia caused by alcoholism and/or psychotropic substance abuse and dependence (including sleeping pills); (7) Those with severe depression and anxiety symptoms; (8) Those with severe headaches, migraine, history of head trauma and surgery; (9) Receiving estrogen, serotonin reuptake inhibitors, or other replacement therapy 4 weeks prior to enrolment; (10) History of anticoagulant use or routine use of sedatives or anxiolytics; (11) Pregnancy or planned pregnancy or breastfeeding; (12) Those with contraindications to magnetic resonance scanning such as claustrophobia, implanted metal in the body, metal braces, etc.

Design outcomes

Primary

MeasureTime frame
Clinical scale assessment;Multimodal neuroimaging assessment;

Secondary

MeasureTime frame
Neuropsychological assessment;

Countries

China

Contacts

Public ContactYu Siyi

Chengdu University of Traditional Chinese Medicine

cdutcmysy@gmail.com+86 136 6817 1182

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026